To determine the structural requirements for parathyroid hormone (PTH) activity in mature bone, we perfused the surgically isolated hindquarters of adult male rats with either native bovine PTH-(1-84) IbPTH-(1-84)i or the synthetic amino-terminal fragment, bovine j. Changes in the release of cyclic AMP (cAMP) and bone Gla protein (BGP) were monitored as evidence of bone-specific response to PTH; tissue specificity of the cAMP response was confirmed through in vitro examination of nonskeletal tissue response to PTH. Biologically active, monoiodinated "I-bbPTH-(1-84) was administered to determine if mature murine bone cleaves native hormone. We found that perfused rat bone continuously releases BGP, and that both bPTH41-84) and bPTH41-34) acutely suppress this release. In addition, both hormones stimulate cAMP release from perfused rat hindquarters. When examined on a molar basis, the magnitude ofthe cAMP response was dose-dependent and similar for both hormones, with doses yielding half-maximal cAMP responses. The response for bPTH41-34) was 0.5 nmol and for bPTH-(1-84) was 0.7 nntol. Moreover, biologically active "SIbPTH41-84) was not metabolized in our hindquarter perfusion system. These findings indicate that PTH41-84) does not require extraskeletal or skeletal cleavage to an amino-terminal fragment in order to stimulate cAMP generation in, or suppress BGP release from, mature rat bone.
Introduction
Parsons and Robinson observed that perfusion of feline tibias with bovine parathyroid hormone (bPTH)' stimulated calcium release from the bone only if the hormone had first been circulated through the whole animal (1) . Their work led to the first suggestion that parathyroid hormone (PTH) requires extraskeletal processing to attain full potency in bone.
Later work showed intact 84-amino acid PTH [PTH-( 1-84)] to be metabolized in liver and kidney to biologically inactive (NH2)-fragments (3) (4) (5) . Both NH2-fragments of PTH and the intact hormone are active in kidney, but information about structural requirements for PTH action in mammalian bone is contradictory. For example, Martin et al. (6) reported perfused canine tibias to selectively take up the amino-terminal fragment of bPTH [bPTH- ], but not bPTH- . Furthermore, only bPTH-(1-34) markedly stimulated release of cyclic AMP (cAMP) from the bones. Findings in other systems differ sharply from Martin's: bPTH-(1-84) is fully potent in activating adenyl cyclase in fetal rabbit calvarial membranes (7) , isolated bone cells from rat calvarias (8) , fetal rat calvarias (9) , chick bone (10) , and isolated chick bone cells (1 1) . Bone may (9) or may not (6) metabolize PTH-( 1-84), but there are no data to verify skeletal production of bioactive NH2-fragments of PTH. Age and species differences in the models used may partly explain the above discrepancies. In any event, the concept that PTH-(1-84) requires extraskeletal cleavage to an NH2-terminal fragment for complete activity in bone is intriguing and possibly of great general importance.
Therefore, we have used the perfused rat hindquarters to test independently the hypothesis that bPTH-( 1-34), but not bPTH-
(1-84), can stimulate skeletal release of cAMP. The model excluded the possibility of PTH metabolism by visceral organs, but maintained the bone intact in situ. We also tested the effects of PTH on skeletal release of bone Gla protein (BGP, or osteocalcin), as a separate assessment ofPTH action on bone. Finally, the studies clearly demonstrated the utility of the perfused rat hindquarters as a system for studies ofmature mammalian skeletal physiology.
Methods
Perfusion technique. The surgically isolated hindlimb technique used in these studies was modified from Bliziotes et al. (12) and Ruderman et al. (13) . The system is shown schematically in Fig. 1 Hormone preparations. In order to assure biological potency of all parathyroid hormone preparations used in our bone perfusion experiments, we assessed their biological activity with the guanyl nucleotideamplified canine renal plasma membrane adenylate cyclase assay ofNissenson et al. (20) . The system included the GTP analog, 5'-guanylimidodiphosphate [Gpp(NH)p] (100 gM), to augment adenylate cyclase sensitivity to PTH, and a phosphodiesterase inhibitor (1.0 mM IBMX). Synthetic bPTH-(1-34) was used as standard. This method produced consistent results in assays repeated over a year. We used bPTH-(1-84) generously provided by Dr. H. T. Keutmann, Massachusetts General Hospital, Boston, MA and synthetic bPTH-(1-34) (Beckman Instruments, Inc., Spinco Div., Palo Alto, CA). The biological activities of these hormones in the canine membrane assay (20) were 535 and 3,470 U/mg, respectively; however, these values differ markedly from the manufacturer's potency estimates of 3,540 U/mg for bPTH-1-84) (Dr. Keutmann, personal communication) and 6,800 U/mg for synthetic bPTH-1-34). Inconsistency in the estimated biological activity of these hormones is probably attributable to differences in the bioassay procedures and conditions. To avoid confusion, and because no rational choice could be made among the bioassay values available, we chose to express the PTH dosages on a molar basis.
A range of molar doses of PTH was used to examine differences in potency of intact hormone and the synthetic fragment. At a given time, we simultaneously infused two hormone preparations in parallel perfusion systems. All hormone doses were combined in 2 ml of KHB buffer containing 3% BSA (vehicle); control perfusions were carried out with vehicle alone.
Hormone cleavage. Biologically active radioiodinated bPTH-(1-84) was prepared and purified as described by Rosenberg et al. (21) and Nissenson et al. (22) . Our objective was to determine whether or not rat bone cleaves native PTH, potentially generating bioactive fragments.
The bPTH-1-84) is labeled with '25I on tyrosine-43 so that metabolism of this molecule to an NH2-terminal fragment would also yield a labeled COOH-terminal fragment. Before iodination, the biological potency of the bPTH-(1-84) was estimated to be 2,650 U/mg using the rat renal membrane adenylate cyclase assay system (21). The specific activity of the preparation used in our studies was 0.012 mU/106 dpm. Biological activity of the '25I-bPTH-( 1-84) preparation was established before use by PTH receptor binding to rat osteosarcoma cells and chicken renal membranes (23) ; it was previously shown that the electrolytic iodination procedure does not decrease the biological potency of PTH (21).
The Iyophilized labeled hormone was reconstituted with 0.01 M acetic acid and aliquoted into doses containing -106 cpm. Each dose was brought up to 2 ml total volume with vehicle for injection into the hindlimb preparation. After delivery of the labeled hormone (over 30 s), we made ten 3-min collections of venous effluent. Approximately 60% of the radioactivity of the injected dose was recovered in the first three venous collection tubes. The cell-free perfusate from these tubes was pooled (-15 ml) and extracted with octadecylsilyl-silica (ODS-silica), using Sep-Pak C18 cartridges (Waters Associates, Milford, MA) as previously described by Bennett et al. (24) . The ODS-silica eluates were diluted 1:4 with 0.13% heptafluorobutyric acid (HFBA) and then chromatographed via reverse-phase high-performance liquid chromatography (HPLC) using a g Bondapak C18 column (Waters Associates) equilibrated with 88% water and HFBA and 10% acetonitrile with HFBA (Waters Associates Automated Gradient Controller model 680 and two model 510 pumps). The sample was perfused with 88% water with HFBA and 12% acetonitrile with HFBA for 3-4 min to concentrate the sample at the column head. The column was eluted with a linear gradient of 28-45% acetonitrile over 50 min at a flow rate of 1.5 ml/min. This was increased to 48% acetonitrile over the next 30 min with no change in the flow rate and then held constant over the next 20 min. Column fractions were collected every minute (model 1220, Isco Inc., Lincoln, NE) in disposable glass test tubes and the radioactivity of each sample was quantified by direct gamma counting.
To verify that the HPLC method we used could detect fragments of PTH, we generated labeled cleavage products by incubating monoiodinated '251-bPTH-(1-84) with purified bovine spleen cathepsin D (Sigma Chemical Co.). Cathepsin D has been identified as an enzyme involved in the generation of COOH-terminal fragments of PTH in vitro (25) (26) . The lyophilized enzyme was reconstituted with 0.05 M ammonium acetate buffer, pH 5.0 and 300 ul (1.5 U) was added to 300 ,ul of 12511 bPTH-( 1-84) (4 X 101 cpm total). The incubation mixture was vortexed and incubated for 15 min at 370C and then brought up to 10 ml total volume with cold vehicle, extracted on silica, and chromatographed as described above. Elution characteristics of bPTH-( 1-84) and bPTH( 1-34) were determined by injecting the iodinated species with and without prior extraction on ODS-silica. The markers eluted at the same position independent of prior ODS-silica extraction. There was a 65% recovery of radioactivity after ODS-silica extraction and better than 90% recovery after HPLC.
Validation studies. Incubation of rat muscle with PTH has been reported by one group (27) to stimulate muscle cAMP accumulation, although another group found no effect (12) . Vasodilatory actions of PTH and possible stimulation ofvascular cAMP accumulation have also been reported (28) (29) (30) . Since muscle and vascular tissue represent a significant amount of the perfused tissue in the hindlimb, it was necessary to show the specificity of the PTH responses.
Epitrochlearis muscles from the forelimbs of 150-g male rats were rapidly dissected, cleaned, weighed, and placed intact in a 37°C oxygenated KHB buffer containing 0.5 mM glucose, 5 mM Hepes, 0.5 mM IBMX, and 3 mg/ml BSA (Cohn fraction V). Before incubation of the muscle, bPTH-( 1-34) (5.6, 2.8, and 1.4 nmol/ml), epinephrine (10-6 M), or vehicle (0.01 mM acetic acid) was added to the medium. The right and left epitrochlearis muscles were randomly assigned to hormonal treatments, incubated at 37°C (95% 02, 5% CO2 atmosphere) in an oscillating water bath for 5 min, then removed, blotted, and frozen in liquid nitrogen for later analyses. Incubation buffer from each muscle was mixed with an equal volume of 0.05 mM NaOAC buffer (pH 5.1), heated in a 90°C water bath for 10 min, then cooled, and centrifuged.
The supernatant was assayed for cAMP as described above, and the results expressed as picomoles cAMP released per gram muscle. We homogenized frozen muscle with a glass-on-glass tissue homogenizer in 1.5 ml of 0.05 mM NaOAc buffer (pH 5.1), containing 0.5 mM IBMX.
Tritiated cAMP (New England Nuclear, Boston, MA) was added to each muscle homogenate to quantitate recovery of the cyclic nucleotide (>85%). The homogenate was heated in a 90°C bath for 10 min, cooled, and the protein pellet separated by centrifugation. The supernatant cAMP content was assayed as described and the results expressed as picomoles cAMP per gram muscle. We also examined the ability of PTH to stimulate cAMP release from rat hindlimb vessels. Sections ofthe external iliac arteries and veins from 350-g male rats were excised and freed of adherent connective tissue while immersed in 40C KHB buffer. The vessels were blotted, weighed, and incubated with bPTH-(1-34) (2.8 nmol/ml), prostaglandin E2 (10 ng/ml), or PTH vehicle (0.01 mM acetic acid) for 5 mm. The incubation media were processed and analyzed as described for muscle, and the results reported as picomoles cAMP released per gram vascular tissue. In addition, we examined the ability of PTH to stimulate cAMP release from isolated murine adipocytes (31) and bone marrow cells (32) .
Statistical analyses. Data are presented as mean±SEM, unless stated otherwise. Student's t test was used to determine significance of differences between results of control and experimental tissue incubations. In experiments involving serial effluent sampling after hormone stimulation, the data were reduced to one response per rat by summation of all responses from the time of hormone delivery to 30 min. Statistical significance of differences was assessed by analysis of variance. When significant differences were indicated, Student-Newman-Keul's test was used to determine which differences were significant.
Results
Viability and system specificity. Fig. 2 Fig. 7 also illustrates the ability of our method (ODS-silica extraction followed by reverse-phase HPLC)to distinguish 1251_ bPTH41-84) from cleavage products generated enzymatically in vitro. From these results, we are confident that the ODS-silica extraction procedure did not cause loss of fragments possibly generated in the hindquarter perfusion. 106 M epinephrine (EPI) (n = 8 for all treatments). Data are mean±SE. Student's t test was used to assess differences between hormone treatment and control vehicle incubation (*P < 0.001).
bioactivity of the two hormones (Fig. 5) . Increasing the dose of PTH gave a biphasic cAMP response, with declining total cAMP release above 6.8 nmol/preparation for bPTH41-84) and 11.6 nmol/preparation for bPTH . The concentrations of bPTH-1-34) and bPTH41-84) required for half maximal release of cAMP were estimated to be 0.5 and 0.7 nmol, respectively.
The rat hindlimbs released immunoreactive BGP, with the release slowly declining over the 120-min perfusion (Fig. 6) . Treatment with bPTH41-84), 6 .85 nmol, produced a significantly greater decrease of BGP release than in vehicle perfused hindquarters. Synthetic bPTH-(l -34), 2.78 nmol, also suppressed BGP release but to a lesser degree. The different magnitude of effects by the two peptides probably resulted from the nearly 2.5-fold difference in dose.
Metabolism ofbiologically active '25I-bPTH-(1-84). .100 
Discussion
The present studies verify that PTH evokes rapid, dose-related increases of cAMP release from perfused rat hindquarters (12) , and suggests that PTH acutely suppresses release of BGP. We believe that both responses reflect the actions of PTH on bone. There is no serious question about specificity of the BGP response, since BGP occurs only in skeletal tissue (33). On the other hand, adenylate cyclase occurs in many tissues; muscle (27) and fat cells (31), and fat cell ghosts (34) reportedly respond to PTH with increased cAMP generation. However, Bliziotes et al. (12) found no effect of bPTH(1-34) on rat muscle cAMP content or release, and repeated trials in our laboratory also showed no effect. In addition, we found no effect of PTH on cAMP release from murine fat cells (31, 34), marrow cells (32) , and blood vessels. Despite the heterogeneity of perfused tissue in this system, we conclude that the BGP and cAMP responses were specific for bone.
Martin et al. (6) found only a weak cAMP response to bPTH-(1-84) in perfused canine tibia, while bPTH-(l-34) markedly stimulated cAMP release. A major finding of the present study was that bPTH-( 1-84) and bPTH-( 1-34) were potent stimulators (9) , but there is no evidence for skeletal production of bioactive PTH fragments. Furthermore, fetal rabbit calvarial membranes responded to bPTH-( 1-84) without apparent ability to metabolize the hormone (7) . Our data clearly demonstrated that perfused murine bone did not cleave intact bPTH-( 1-84) during a single pass. In addition, chromatography of effluent collected later than 12 min after hormone delivery revealed no new peaks, indicating that any delay in the release of the hormone was not due to skeletal cleavage. These findings further suggest that native PTH requires no metabolic activation for full potency in adult rat bone. while the responses to doses of bPTH-( 1-84) beyond this range plateaued or declined. We have no ready explanation for this phenomenon, but it strongly suggests that potency comparisons of PTH and its analogs must encompass full dose-response curves, to obtain complete information. These findings also demonstrate that potency comparisons of PTH preparations made in kidney may not accurately reflect their relative potencies in bone. The synthetic bPTH-(1-34) was 2.8-fold more potent than the native bPTH-( 1-84) when bioassayed in the canine renal plasma membrane adenylate cyclase system, while these hormone preparations were essentially equipotent in our perfused bone system. These differences in potency estimates strongly suggest that careful consideration be given to the choice oforgan system and species used to test the efficacy of PTH analogs.
Another important finding in these studies was that BGP was released continuously from perfused rat bone; moreover, this release acutely responded to PTH. Administration of bPTH-(1-84) and bPTH-( 1-34) suppressed BGP release to below that of vehicle-perfused rats. The difference in the degree of suppression observed between the two hormonal treatments suggests that the magnitude of BGP suppression by PTH may be dosedependent in perfused whole bone, as it was in bone cells (36 
